Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
J Neurooncol
; 143(2): 241-249, 2019 Jun.
Article
in En
| MEDLINE
| ID: mdl-31025274
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Glioblastoma
/
Receptors, CXCR4
/
Myeloid Cells
/
Programmed Cell Death 1 Receptor
/
Antineoplastic Agents, Immunological
/
Immunotherapy
Type of study:
Clinical_trials
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
J Neurooncol
Year:
2019
Document type:
Article
Affiliation country:
United States
Country of publication:
United States